drugset / Trial / NCT02890069
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Timeline
- Start
- 2016-10-14
- Primary completion
- 2022-02-22
- Completion
- 2022-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | — |
| Subject | LCL161 | Small molecule | — | — |
| Subject | Panobinostat | Small molecule | — | — |
| Subject | QBM076 | Unknown | — | — |
| Subject | Siremadlin | Small molecule | — | — |
| Subject | Spartalizumab | Monoclonal antibody | — | — |